Targeting the Janus kinases in rheumatoid arthritis: Focus on tofacitinib

Kunihiro Yamaoka, Yoshiya Tanaka

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK), which is activated immediately after cytokines bind to their receptor within the cytoplasmic membrane. Areas covered: Tofacitinib is an orally available tablet and treatment efficacy is similar to biologic DMARDs. Pharmacokinetics, and drug-drug interaction is covered in this article. In addition, efficacy and adverse events from the Phase II and Phase III are overviewed. Additionally, the authors have described the novel mechanism of action (MOA) of tofacitinib in relevance to efficacy and adverse events. Because of its MOA, greater caution is necessary for selecting appropriate patients for treatment initiation and further treatment continuation following clinical trials. Expert opinion: Tofacitinib is a new class of DMARDs orally available with a new mechanism of action and with strong clinical efficacy similar to biologic DMARDs. Multiple cytokines and signaling pathways are partially inhibited at clinical doses that are in contrast to biological DMARDs. Further investigation is necessary to come to a conclusion on risk-benefit ratio and selection of patients.

Original languageEnglish
Pages (from-to)103-113
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number1
DOIs
Publication statusPublished - 2014 Jan
Externally publishedYes

Fingerprint

Janus Kinases
Antirheumatic Agents
Rheumatoid Arthritis
Cytokines
Expert Testimony
Drug Interactions
Protein-Tyrosine Kinases
Patient Selection
Tablets
Therapeutics
Pharmacokinetics
Odds Ratio
Cell Membrane
tofacitinib
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Janus kinase
  • Rheumatoid arthritis treatment
  • Tofacitinib

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Targeting the Janus kinases in rheumatoid arthritis : Focus on tofacitinib. / Yamaoka, Kunihiro; Tanaka, Yoshiya.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 1, 01.2014, p. 103-113.

Research output: Contribution to journalArticle

Yamaoka, Kunihiro ; Tanaka, Yoshiya. / Targeting the Janus kinases in rheumatoid arthritis : Focus on tofacitinib. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 1. pp. 103-113.
@article{79afe1be57d5437ab6d8882c40428dc1,
title = "Targeting the Janus kinases in rheumatoid arthritis: Focus on tofacitinib",
abstract = "Introduction: Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30{\%}. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK), which is activated immediately after cytokines bind to their receptor within the cytoplasmic membrane. Areas covered: Tofacitinib is an orally available tablet and treatment efficacy is similar to biologic DMARDs. Pharmacokinetics, and drug-drug interaction is covered in this article. In addition, efficacy and adverse events from the Phase II and Phase III are overviewed. Additionally, the authors have described the novel mechanism of action (MOA) of tofacitinib in relevance to efficacy and adverse events. Because of its MOA, greater caution is necessary for selecting appropriate patients for treatment initiation and further treatment continuation following clinical trials. Expert opinion: Tofacitinib is a new class of DMARDs orally available with a new mechanism of action and with strong clinical efficacy similar to biologic DMARDs. Multiple cytokines and signaling pathways are partially inhibited at clinical doses that are in contrast to biological DMARDs. Further investigation is necessary to come to a conclusion on risk-benefit ratio and selection of patients.",
keywords = "Janus kinase, Rheumatoid arthritis treatment, Tofacitinib",
author = "Kunihiro Yamaoka and Yoshiya Tanaka",
year = "2014",
month = "1",
doi = "10.1517/14656566.2014.854771",
language = "English",
volume = "15",
pages = "103--113",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Targeting the Janus kinases in rheumatoid arthritis

T2 - Focus on tofacitinib

AU - Yamaoka, Kunihiro

AU - Tanaka, Yoshiya

PY - 2014/1

Y1 - 2014/1

N2 - Introduction: Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK), which is activated immediately after cytokines bind to their receptor within the cytoplasmic membrane. Areas covered: Tofacitinib is an orally available tablet and treatment efficacy is similar to biologic DMARDs. Pharmacokinetics, and drug-drug interaction is covered in this article. In addition, efficacy and adverse events from the Phase II and Phase III are overviewed. Additionally, the authors have described the novel mechanism of action (MOA) of tofacitinib in relevance to efficacy and adverse events. Because of its MOA, greater caution is necessary for selecting appropriate patients for treatment initiation and further treatment continuation following clinical trials. Expert opinion: Tofacitinib is a new class of DMARDs orally available with a new mechanism of action and with strong clinical efficacy similar to biologic DMARDs. Multiple cytokines and signaling pathways are partially inhibited at clinical doses that are in contrast to biological DMARDs. Further investigation is necessary to come to a conclusion on risk-benefit ratio and selection of patients.

AB - Introduction: Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK), which is activated immediately after cytokines bind to their receptor within the cytoplasmic membrane. Areas covered: Tofacitinib is an orally available tablet and treatment efficacy is similar to biologic DMARDs. Pharmacokinetics, and drug-drug interaction is covered in this article. In addition, efficacy and adverse events from the Phase II and Phase III are overviewed. Additionally, the authors have described the novel mechanism of action (MOA) of tofacitinib in relevance to efficacy and adverse events. Because of its MOA, greater caution is necessary for selecting appropriate patients for treatment initiation and further treatment continuation following clinical trials. Expert opinion: Tofacitinib is a new class of DMARDs orally available with a new mechanism of action and with strong clinical efficacy similar to biologic DMARDs. Multiple cytokines and signaling pathways are partially inhibited at clinical doses that are in contrast to biological DMARDs. Further investigation is necessary to come to a conclusion on risk-benefit ratio and selection of patients.

KW - Janus kinase

KW - Rheumatoid arthritis treatment

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84890654789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890654789&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.854771

DO - 10.1517/14656566.2014.854771

M3 - Article

C2 - 24188100

AN - SCOPUS:84890654789

VL - 15

SP - 103

EP - 113

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -